Reimbursement for switching between severe atopic dermatitis drugs may be approved soon in Korea. However, further efforts by pharmaceutical companies would be needed to share the additional finances required. Therefore, it is analyzed that pharmaceutical companies will overcome the Health Insurance Review and Assessment Service’s review process by voluntarily reducing their drug price.

According to industry sources on the 25th, voluntary price reductions are being discussed to receive reimbursement for switching between severe atopic dermatitis drugs.

The reimbursement standards for switching between biologics and JAK inhibitors have already been established through expert disc